11 Best Performing Stocks So Far In 2025

Page 7 of 10

4. Chimerix Inc. (NASDAQ:CMRX)

Year-to-Date Performance as of March 21: 143.39%

Number of Hedge Fund Holders: 17

Chimerix Inc. (NASDAQ:CMRX) is a biopharmaceutical company that develops therapies for life-threatening diseases. Its pipeline includes ONC201 for glioma and neuroendocrine tumors, ONC206 for CNS tumors, ONC212 for oncology indications, and CMX521 for SARS-CoV-2.

The company’s main focus is securing FDA approval for Dordaviprone, which is a potential treatment for a rare and aggressive brain cancer. The FDA has accepted the company’s application and granted it Priority Review, with a decision expected by August 18 this year. If approved, Dordaviprone would be the first specific treatment for this type of cancer. The company is preparing for a potential commercial launch as well.

Dordaviprone has received Rare Pediatric Disease Designation and has applied for a Rare Pediatric Disease Priority Review Voucher (PRV). Dordaviprone also has Fast-Track Designation in the US and Orphan Drug Designation in the US, Europe, and Australia. At the end of 2024, the company had $140.1 million in available capital. Jazz Pharmaceuticals is set to acquire Chimerix Inc. (NASDAQ:CMRX) for $935 million in Q2 of 2025, which underscores the value of Dordaviprone.

Page 7 of 10